The vaccine has been shown to be effective
in preventing and/or reducing the severity
of RSV infections and the number
of hospitalizations each year.
Infants who are a product of multiple births, have lung disease, low birth weight, heart disease, and those born prematurely are at a higher risk to contract a serious form of Resipritory Syncytial Virus.